Forbion, Fountain et al. in £23m series-B for Nerre Therapeutics
Forbion Capital, Fountain Healthcare Partners and Orbimed have joined in a £23m series-B for British biotech startup Nerre Therapeutics.
Alongside the new backers, existing investors Advent Life Sciences and Danish pharmaceutical group Novo also participated.
Nerre intends to use the fresh funding to support clinical trials of certain therapeutics the company is developing.
The round was led by Fountain, while Forbion and Orbimed co-led the series-B.
Company
Nerre is a biotechnology company developing treatments for common, chronic and debilitating conditions caused by neuronal hypersensitivity.
The business is based in Stevenage, having spun out of Glaxo Smith Kline in 2012.
People
Nerre Therapeutics– Mary Kerr (CEO).
More on Healthcare
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
Czech Republic-headquartered family office is targeting DACH and CEE region deals
CMA scrutiny of high-leverage PE divestment purchases expected to increase
PE could stand to lose its historic advantage with heightened regulatory baggage
Evoco expects portfolio acquisitions, assesses potential exits in 2H23
Switzerland-headquartered GP is currently deploying equity via its EUR 162m Evoco TSE III fund
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater